AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Allergan150 enrolled

Overview

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

150

Conditions

Peptic Ulcer

Interventions

AGN 201904DRUG

esomeprazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Adult Volunteers who have provided written informed consent Exclusion Criteria: * Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease. * Female volunteers who pregnant, nursing, or planning a pregnancy * Volunteers with a history of drug or alcohol abuse

Locations (1)

Unnamed facility

Houston, Texas, United States

Outcomes

Primary Outcomes

Stomach or upper intestinal erosions

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.